



**ORHUB, INC.**

**OTC PINK BASIC QUARTERLY INFORMATION  
AND DISCLOSURE STATEMENT**

**AS OF MARCH 31, 2017**

## ORHUB, INC.

### OTC PINK BASIC QUARTERLY INFORMATION AND DISCLOSURE STATEMENT

AS OF MARCH 31, 2017

#### **The Company**

On June 30, 2016, MemReg, Inc. (the “*Company*”) acquired all the assets and business of ORhub, LLC (“*ORH*”) in exchange for 102,694,775 shares of common stock and assumption of certain ORH liabilities (the “*Acquisition*”). ORH was developing a proprietary, 100% cloud based software application for the management of device implant and biologic inventory (the “*ORhub Software*”). As a condition of the closing of the Acquisition, the Company divested its memorabilia business operated through its wholly owned subsidiary, Memorabilia Registry Corp. (“*MRC*”), through a tax-free split-off of MRC (the “*Split-off*”). To affect the Split-off, certain stockholders exchanged all the Company’s outstanding Series C Preferred stock and 9,447,602 shares of common stock for all the outstanding capital stock of MRC. As a result of the Acquisition and divestiture of MRC, the Company will focus on the development of the ORhub business. Effective August 22, 2016, the Company changed its name and received regulatory approval on February 9, 2017, at which time FINRA authorized a symbol change from MREG to ORHB.

#### **ORhub’s Business**

ORhub is a software as a service (SaaS) company that is bringing significantly enhanced productivity to the business of implant surgery and eventually to all surgeries. The Company estimates its initial market to be in excess of 7,000,000 surgeries per year and, because of the “baby boomers,” growth in this market is expected to accelerate. The implant accounting process hasn’t changed since implants became a big part of surgical volume. It is still based on manual notetaking, a laborious approval cycle and then siloed data entry. This process is slow, labor intensive, prone to inaccuracies and filled with non-value added activity that utilizes the nursing staff. It is costly for Hospitals to individually address this obvious productivity problem because of their legacy IT systems.

ORhub has teamed with two major hospitals to refine its product and service line modules. The ORhub System is tablet-based with a powerful and intuitive graphical interface, and ability to track implants and other materials used in surgery from the point of delivery for a case through the billing cycle and into outcome correlation metrics. Data is captured during a surgery and uploaded to the Company’s “cloud” for processing in a secure and HIPPA compliant manner. Data is then used for analytics and cost optimization to drive a true value-based measurement effort. The data is designed from inception to allow search, self-service, and analytics at the case level for hospital administrators and physicians. The Company is now the system of record for every spine surgery performed by the Company’s two development partners, and is releasing a sterilization and Hip & Knee module in late Q1 and

---

#### **ORHUB, INC.**

OTC PINK BASIC QUARTERLY INFORMATION  
AND DISCLOSURE STATEMENT  
AS OF THE QUARTER ENDING MARCH 31, 2017

early Q2 of fiscal 2018 (August – October 2017). In addition, the platform has generated significant value in one of the most efficient for profit hospitals in the country. The implication is that for hospitals not as efficiently run, the margins and savings opportunity can be significantly higher than those currently being measured.

### **The Software is completed and in use daily**

The Company is beyond the risk that its software will not be operational. It picked the most complex implant surgery, spine implants, to fully develop its software. The Company is currently planning on deploying two other service line modules by Q4 this year. All other implants are less complex than spines, but with very similar process flows and data elements. The Company has processed in excess of 500 surgeries and this count is increasing daily.

### **Prior history and development of Issuer**

The Company was originally incorporated in Arizona on September 3, 2004 under the name VT Gaming Services, Inc. (“VTG”) to implement the confirmed Chapter 11 Bankruptcy Plan (the “Plan”) of Visitalk.com, Inc. (the “Debtor”). At the time of confirmation of the Plan, VTG was capitalized with a license to the Debtor’s technology with use limited to facilitate peer-to-peer computer gaming activities. Pursuant to the Plan, creditors and claimants of the Debtor received stock and warrants in VTG (see Items 3(A)2(a) and 3(C) below). On December 31, 2004, pursuant to an Exchange Agreement, the Company acquired all of the outstanding capital stock of DynaSig Corporation, an Arizona corporation (“DynaSig”). The related change of control caused the peer-to-peer license and all related development to revert to the Reorganized Debtor, Visitalk Capital Corp. Reflecting this change in business, in 2005 the Company changed its name to Dynamic Biometric Systems, Inc. and changed its state of incorporation from Arizona to Nevada. In 2009, the Company refocused on the memorabilia business by forming MRC. In December 2013, the Company restructured its operations by selling DynaSig and focusing on the memorabilia business.

### **ITEM 1) NAME OF THE ISSUER AND ITS PREDECESSORS (IF ANY)**

Effective August 22, 2016, the Company changed its name and received regulatory approval on February 9, 2017, at which time FINRA authorized a symbol change from MREG to ORHB. In April 2011, the Company had changed its name from Dynamic Biometric Systems, Inc. (“DYBO”) to MemReg, Inc. This name change was approved at the opening of business January 2, 2015 when the Company’s trading symbol was changed from DYBO to MREG. Effective December 31, 2004, the Company changed its name from VT Gaming, Inc., an Arizona corporation, to DYBO when it changed its state of domicile to Nevada from Arizona.

**ITEM 2) ADDRESS OF THE ISSUER'S PRINCIPAL EXECUTIVE OFFICES**

Company Headquarters

Address 1: 9830 South 51st Street  
Address 2: Suite A-128  
Address 3: Phoenix, Arizona 85044  
Phone: (844)545-4508, ext. 402  
Email: [info@orhub.com](mailto:info@orhub.com)  
Corporate website: [www.orhub.com](http://www.orhub.com)

IR Contact

Firm: None  
Phone: (844)545-4508, ext. 402  
Email: [mike.williams@orhub.com](mailto:mike.williams@orhub.com)  
Corporate website: [www.orhub.com](http://www.orhub.com)

**ITEM 3) SECURITY INFORMATION**

A. Exact title and class of securities outstanding: **Common Stock**  
Trading Symbol: ORHB  
CUSIP: 68620R 107  
Par or Stated Value: \$.001  
Total shares authorized: 190,000,000 as of: 3/31/2017  
Total shares outstanding: 127,791,444 as of: 3/31/2017  
Total shares reserved: 47,050,000 as of: 3/31/2017

Transfer Agent for the Common stock

Name: Computershare Trust Company, NA.  
Address 1: 8742 Lucent Boulevard  
Address 2: Suite 255  
Address 3: Highlands Ranch, Colorado 80219  
Phone: (303) 262-0678

Is this Transfer Agent registered under the Exchange Act?\* Yes:  No:

List any restrictions on the transfer of security:

1. Restricted - A majority of the shares of common stock were issued in private transactions or without other exemptions and are therefore restricted securities requiring a registration or exemption from registration to be "free trading."

2. Non-Restricted

(a) *Prior to June 30, 2016.* Pursuant to the Plan confirmed in 2004, in which the Company was a co-proponent, approximately 220,000 shares were issued to

non-affiliates. In 2005, 124,125 shares of common stock and in 2014, 130,466 shares of common stock were issued through the exercise of Plan Warrants (see Item 3C below). These shares of common stock issued pursuant to the Plan and the exercise of the Plan Warrants were issued pursuant to Section 1145 of the Bankruptcy Code and are “free trading.”

(b) *Nine months ending March 31, 2016.* On July 8, 2016, the Company established a Special Exercise Price of the Plan Warrants of \$.3333 (See Plan Warrants under C of this section). During the nine months ended March 31, 2017, 10,554,273 Plan Warrants were exercised at the Special Exercise Price and the Company received proceeds of \$3,517,730 in cash and notes for cash and notes. The shares of common stock issued pursuant to exercise of these Plan Warrants was exempt from registration pursuant to Section 1145 of the Bankruptcy Code and are “free trading.”

B. Additional class of securities: **Undesignated Preferred**

Trading Symbol:	none
CUSIP:	no CUSIP – n/a
Par or Stated Value:	to be determined by the Board of Directors
Total shares authorized:	7,775,827 as of: 3/31/2017

**Preferred Stock Transfer Agent**

Name:	<u>If designated</u> , the Company will act as its own transfer agent
Address 1:	9830 South 51st Street
Address 2:	Suite A-128
Address 3:	Phoenix, Arizona 85044
Phone:	(844) 545-4508, ext. 402

Is the Transfer Agent registered under the Exchange Act?\* Yes:  No:

List any restrictions on the transfer of security:

All previously designated series of Preferred stock have been withdrawn and now there are no designated classes of preferred stock.

C. Additional class of securities: **Plan Warrants**

The Company has five series of common stock purchase warrants outstanding allowing holders to purchase additional shares of common stock. All these warrants were issued under the Plan (“*Plan Warrants*”). Each Plan Warrant provides for the purchase of one share of common stock and is callable at any time by the Company for a price of \$.0001 per warrant. The Plan Warrants are governed by a Warrant Agreement. Currently, the Company is acting as the Warrant Agent but has the right to appoint an alternative Warrant Agent in accordance with the Warrant Agreement. Pursuant to the Plan, the Company’s Board of Directors can

extend the expiration date of the Plan Warrants or reduce the exercise price of any Plan Warrant on a temporary or permanent basis.

Pursuant to the Warrant Agreement, without Company approval, a holder may not exercise Warrants which when combined with current beneficial ownership would increase such holder's ownership in the Company above 5%. On August 1, 2016, in response to a request, the Company waived the 5% ownership restriction for six large shareholders who owned greater than 5% of the Company in exchange for undertakings regarding current information to meet the Company's disclosure requirements.

A summary of the Warrants outstanding as of March 31, 2017, is as follows:

	Series B Warrants	Series C & D Warrants	Series E & F Warrants
Warrants outstanding, June 30, 2016	8,293,025	16,846,982	16,846,982
Exercised	3,754,362	4,051,876	2,748,035
Expired	-	-	-
Warrants outstanding, March 31, 2016	<u>4,538,663</u>	<u>12,795,106</u>	<u>14,098,947</u>
Exercise price (1)	<u>\$ 2.00</u>	<u>\$ 3.00</u>	<u>\$ 4.00</u>
Warrant Expiration date	<u>Dec. 31, 2017</u>	<u>Dec. 31, 2017</u>	<u>Dec. 31, 2017</u>

(1) On July 8, 2016, the board of directors approved reducing the exercise price of all Plan Warrants to \$.3333 (the "*Special Exercise Price*") which initially expired on October 6, 2016. The board of directors extended the Special Exercise Price until December 5, 2016 but only for the Series B Plan Warrants. The Special Exercise was extended again for all Plan Warrants until February 27, 2017. During the nine months ended March 31, 2017, 10,554,273 Plan Warrants were exercised at the Special Exercise Price and the Company received proceeds of \$3,517,730 in cash and notes for cash and notes. As of February 28, 2017, the Plan Warrants have reverted to their original exercise prices.

1. Exact title and class of securities outstanding: **Plan Warrant Unit**

The Plan Warrant Unit which existed at June 30, 2016 consisted of the five Plan Warrants outstanding and was immediately detachable. Because of the disparate exercise of one Series of Plan Warrants vs. another, the Company determined that the Plan Warrant Unit was impractical and was not be renewed upon its expiration n December 31, 2016. The Unit has been permanently detached into its components; Plan Warrants Series B, C, D, E and F.

2. Exact title and class of securities outstanding: **Series B Plan Warrants**  
Trading Symbol: none  
CUSIP: 68620R 115– transferable but no trading market

Par or Stated Value: Exercise price maximum \$2.00 or adjusted downward as determined by the Board of Directors

Total Series B Plan Warrants authorized: 4,538,663 as of: 3/31/2017. No additional Series B Warrants can be authorized and therefore the authorized equals the outstanding Plan Warrants.

3. Exact title and class of securities outstanding: **Series C Plan Warrants**  
Trading Symbol: none  
CUSIP: 68620R 123 – transferable but no trading market  
Par or Stated Value: Exercise price maximum \$3.00 or adjusted downward as determined by the Board of Directors  
Total Series C Plan Warrants authorized: 6,041,402 as of: 3/31/2017. No additional Series C Warrants can be authorized and therefore the authorized equals the outstanding Plan Warrants.
  
4. Exact title and class of securities outstanding: **Series D Plan Warrants**  
Trading Symbol: none  
CUSIP: 68620R 131– transferable but no trading market  
Par or Stated Value: Exercise price maximum \$3.00 or adjusted downward as determined by the Board of Directors  
Total Series D Plan Warrants authorized: 6,753,704 as of: 3/31/2017. No additional Series D Warrants can be authorized and therefore the authorized equals the outstanding Plan Warrants.
  
5. Exact title and class of securities outstanding: **Series E Plan Warrants**  
Trading Symbol: none  
CUSIP: 68620R 149 – transferable but no trading market  
Par or Stated Value: Exercise price maximum \$4.00 or adjusted downward as determined by the Board of Directors  
Total Series E Plan Warrants authorized: 7,005,308 as of: 3/31/2017. No additional Series E Warrants can be authorized and therefore the authorized equals the outstanding Plan Warrants.
  
6. Exact title and class of securities outstanding: **Series F Plan Warrants**  
Trading Symbol: none  
CUSIP: 68620R 156 – transferable but no trading market  
Par or Stated Value: Exercise price maximum \$4.00 or adjusted downward as determined by the Board of Directors  
Total Series F Plan Warrants authorized: 7,093,639 as of: 3/31/2017. No additional Series F Warrants can be authorized and therefore the authorized equals the outstanding Plan Warrants.

**Transfer Agent for all Series of Plan Warrants**

Name: ORhub, Inc. (the Company acts as its own transfer

agent for all Series of Plan Warrants)  
Address 1: 9830 S. 51st Street  
Address 2: Suite A-128  
Address 3: Phoenix, AZ 85044  
Phone: (844)545-4508, ext. 403

Is the Transfer Agent registered under the Exchange Act?\* Yes:  No:

List any restrictions on the transfer of security:

All the Plan Warrants (the Series B through Series F Plan Warrants) and any shares of common stock issued to non-affiliates through their exercise are unrestricted securities as provided under Section 1145 of the Bankruptcy Code. Shares of common stock issued to affiliates through their exercise may be subject to Rule 144 and, in particular, the “dribble” rule.

D. Describe any trading suspension orders issued by the SEC in the past 12 months.

None

E. List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

As a condition to closing the Acquisition, the Company consummated a tax free “Split-off” of MRC to certain stockholders. The Company received all the shares of its Series C Preferred outstanding (775,000 shares) plus 9,447,602 shares of its common stock in exchange for all outstanding shares of MRC. The shares of Series C Preferred stock and the 9,447,602 shares of common stock acquired by the Company in the split-off were retired and returned to the status of authorized and unissued shares. The MRC shares transferred in the split-off were not registered in reliance of Section 4(2) of the Securities Act of 1933. The Company shares retained by the “splitting off” shareholders (3,226,227) qualified for the removal of the restrictive legend on these residual shares under Rule 144.

#### **ITEM 4) ISSUANCE HISTORY**

List below any events, in chronological order, that resulted in changes in total shares outstanding by the issuer in the past two fiscal years and any interim period.

#### **Reconciliation Table of items changing outstanding shares of common stock:**

1. Common shares outstanding at December 31, 2014	20,051,436
2. Common shares issued for debt (see Detail 4-2 below)	3,400,000
3. Common shares issued for ORH Assets (see 4-3 below)	102,694,775

4. <b>Less:</b> Shares returned to the Treasury (see 4-4 below)	(9,447,603)
5. Total shares outstanding at June 30, 2016	<u>116,698,608</u>
6. Common shares issued in a private placement (see 4-6 below)	538,563
7. Common shares issued for Plan Warrant exercises (see 4-7) below	10,554,273
8. <b>Total shares outstanding at March 31, 2017</b>	<u><u>127,791,444</u></u>

The items on the Reconciliation Table are presented in more detail below and include all offerings of equity securities, including debt convertible into equity securities, whether private or public, and all shares or any other securities or options to acquire such securities issued for services, describing (1) the securities, (2) the persons or entities to whom such securities were issued and (3) the services provided by such persons or entities. The listing shall indicate the nature of the issuance, the jurisdiction and distribution, the shares offered or issued, the shares finally issued and their price, the trading status of the shares issued and if they are restricted.

#### **Issuance 4-2 from the Reconciliation Table**

- A. Nature of the issuance. On September 1, 2015, the Company converted approximately \$285,600 of debt into 3,400,000 shares of common stock valued at \$.084. These securities were issued under Section 4(2) of the Securities Act of 1933.
- B. Jurisdictions and distribution. Issuances specified in Section 4-2 were limited private offerings made in reliance on the exemption for registration provided under Section 4(2) of the Securities Act of 1933;
- C. Shares offered. 3,400,000 shares of common stock to retire debt (see 4-1 above);
- D. Shares sold. 3,400,000 shares of common stock to retire debt (see 4-1 above);
- E. Price offered and sold. The 3,400,000 shares of common stock issued to retire debt were issued for \$.084 per share;
- F. Trading status. The 3,400,000 shares of common stock are restricted securities
- G. Legend. Yes, the 3,400,000 shares of common stock issued to retire debt were issued with a restrictive legend

### **Issuance 4-3 from the Reconciliation Table**

- A. Nature of the issuance. On June 30, 2016, under the terms of an Asset Purchase Agreement (the “*APA*”), the Company acquired all the assets and assumed certain liabilities of ORhub, including its name, business, technology, website, and intellectual property. The Company issued 102,694,775 shares of its common stock, representing 88.0% of the common stock of the Company at the closing of the APA. For accounting purposes, ORhub will be deemed to be the accounting acquirer in the transaction and, consequently, the transaction will be treated as a recapitalization of the Company. As a result of this accounting treatment, ORhub’s financial statements, with required adjustments, become the historical financial statements of the Company and the Company’s assets, liabilities, and results of operations are consolidated with ORhub effective as of the date of the closing of the APA. No step-up in basis or intangible assets or goodwill will be recorded in this transaction. These securities were issued under Section 4(2) of the Securities Act of 1933.
- B. Jurisdictions and distribution. Issuances specified in Issuance 4-3 were limited private offerings made in reliance on the exemption for registration provided under Section 4(2) of the Securities Act of 1933 and made only to ORhub, LLC;
- C. Shares offered. 102,694,775 shares of common stock to acquire assets (see 4-3 above);
- D. Shares sold. 102,694,775 shares of common stock to acquire assets (see 4-3 above);
- E. Price offered and sold. The 102,694,775 shares of common stock issued to acquire the assets was a tax-free, assets for stock exchange with no attributable price to the buyer.
- F. Trading status. The 102,694,775 shares of common stock are restricted securities
- G. Legend. Yes, the 102,694,775 shares of common stock issued to acquire the assets and business of ORhub, LLC and such shares were issued with a restrictive legend

### **Retirement 4-4 from the Reconciliation Table**

- A. Nature of the issuance. On June 30, 2016, as a condition of the Asset Purchase Agreement (the “*APA*”), the Company “split-off” its Memorabilia Registry Corp. (“MRC”) wholly owned subsidiary in exchange for the return to the Company’s Treasury of 9,447,603 shares of common stock and all the outstanding Series C Preferred shares. All these shares were returned to the Company’s treasury.
- B. Jurisdictions and distribution. Issuances specified in Retirement 4-4 were limited private offerings made in reliance on the exemption for registration provided under Section 4(2) of the Securities Act of 1933 and made only to select shareholders of the Company.
- C. Shares offered to be acquired. 9,447,603 shares of common stock to acquire the shares of MRC (see 4-4 above) and all the outstanding Series C Preferred shares;

D. Shares surrendered. 9,447,603 shares of common stock to acquire the shares of MRC (see 4-4 above) and all the outstanding Series C Preferred shares;

E. Price offered and sold. The 9,447,603 shares of common stock issued to acquire the assets was a tax-free split-off with the retention by the MRC recipients of some Company shares. The Company recognized no additional gain or loss on this transaction for book purposes.

F. Trading status. The 9,447,603 shares of common stock returned to treasury are no longer tradable.

G. Legend. n/a

#### **Issuance 4-6 from the Reconciliation Table**

A. Nature of the issuance. On June 30, 2016, under the terms of the APA, the Company assumed ORH's commitment to issue additional equity interests. The Company fulfilled that commitment by issuing 538,563 shares of common stock to a single buyer for \$161,569. These securities were issued under Section 4(2) of the Securities Act of 1933.

B. Jurisdictions and distribution. Issuances specified in Issuance 4-3 were limited private offerings made in reliance on the exemption for registration provided under Section 4(2) of the Securities Act of 1933 and made only to ORhub, LLC;

C. Shares offered. 538,563 shares of common stock (see 4-6 above);

D. Shares sold. 538,563 shares of common stock was acquired for cash (see 4-6 above);

E. Price offered and sold. The 538,563 shares of common stock were priced at \$.30 per share.

F. Trading status. The 538,563 shares of common stock are restricted securities

G. Legend. Yes, the 538,563 shares of common stock were issued with a restrictive legend

#### **Issuance 4-7 from the Reconciliation Table**

A. Nature of the issuance. Starting on July 8, 2016, pursuant to its rights under the Plan Warrants, the Board of Directors temporarily reduced the exercise prices of all the Plan Warrants to \$.3333. This "Special Exercise Price" was extended various times through October 6, 2016. At that date, the Board restricted the Special Exercise Price to only the Series B Plan Warrants and the Series C through F Plan Warrants reverted to their Plan exercise prices of \$3.00 and \$4.00. On December 6, 2016, the Board extended the Special

Exercise Price to all the Plan Warrant Series until February 27, 2017. On February 27, 2017, the Plan Warrants reverted to the Plan exercise price of \$2.00 through \$4.00 depending on the Series. During the nine months ended March 31, 2017, 10,554,273 Plan Warrants were exercised at the Special Exercise Price and the Company received proceeds of \$3,517,730 in cash and notes for cash and notes. Any securities issued through the exercise of any of the Plan Warrants are issued under Section 1145 of the Bankruptcy Code.

B. Jurisdictions and distribution. Any issuances specified in Issuance 4-7 through the exercise of any of the Plan Warrants were issued under Section 1145 of the Bankruptcy Code;

C. Shares offered. 10,554,273 shares of common stock were issued due to warrant exercises (see 4-7 above);

D. Shares exercised (sold). 10,554,273 shares of common stock purchase warrants were exercised for cash and notes (see 4-7 above);

E. Price paid for exercise. \$.3333 per share were paid for the 10,554,273 shares of common stock issued through exercise of the Plan Warrants;

F. Trading status. The 10,554,273 shares of common stock are free trading securities pursuant to Section 1145 of the Bankruptcy Code; and

G. Legend. Since the securities are free trading they were issued without and restrictive legend

**ITEM 5) FINANCIAL STATEMENTS – UNAUDITED (\*)**

As discussed in Item 4-3 of the Reconciliation table above, ORhub is deemed to be the acquirer in the Acquisition. Therefore, ORhub’s operations are deemed to have commenced at its date of inception, November 12, 2015. Because of this treatment, the financial statements for the quarter ended March 31, 2017 are not comparable with the financial statements for the quarter ended March 31, 2016. These financial statements were prepared in accordance with US GAAP.

<b>ORhub, Inc. – Unaudited Financial Statements – March 31, 2017 (*)</b>	<b>Page</b>
Balance Sheet (unaudited) as of March 31, 2017	F-3
Statement of Operations (unaudited) for the three and nine months ended March 31, 2017	F-4
Statement of Cash Flows (unaudited) for the nine months ended March 31, 2017	F-5

(\*) **Filed separately and incorporated herein by reference**

## **ITEM 6) DESCRIBE THE ISSUER'S BUSINESS, PRODUCTS AND SERVICES**

A. A description of the issuer's business operations:

### **ORhub's Business**

ORhub is a software as a service (SaaS) company that is bringing significantly enhanced productivity to the business of implant surgery and eventually to all surgeries. The Company estimates its initial market to be in excess of 7,000,000 surgeries per year and, because of the "baby boomers," growth in this market is expected to accelerate. The implant accounting process hasn't changed since implants became a big part of surgical volume. It is still based on manual notetaking, a laborious approval cycle and then siloed data entry. This process is slow, labor intensive, prone to inaccuracies and filled with non-value added activity that utilizes the nursing staff. It is costly for Hospitals to individually address this obvious productivity problem because of their legacy IT systems.

ORhub has teamed with two major hospitals to refine its product and service line modules. The ORhub System is tablet-based with a powerful and intuitive graphical interface, and ability to track implants and other materials used in surgery from the point of delivery for a case through the billing cycle and into outcome correlation metrics. Data is captured during a surgery and uploaded to the Company's "cloud" for processing in a secure and HIPPA compliant manner. Data is then used for analytics and cost optimization to drive a true value-based measurement effort. The data is designed from inception to allow search, self-service, and analytics at the case level for hospital administrators and physicians. The Company is now the system of record for every spine surgery performed by the Company's two development partners, and is releasing a sterilization and Hip & Knee module in late Q1 and early Q2 of fiscal 2018 (August – October 2017). In addition, the platform has generated significant value in one of the most efficient for profit hospitals in the country. The implication is that for hospitals not as efficiently run, the margins and savings opportunity can be significantly higher than those currently being measured.

### **The Software is completed and in use daily**

The Company is beyond the risk that its software will not be operational. It picked the most complex implant surgery, spine implants, to fully developed its software. The Company is currently planning on deploying two other service line modules by Q4 this year. All other implants are less complex than spines, but with very similar process flows and data elements. The Company has processed in excess of 500 surgeries and this count is increasing daily.

### **The Company's Market**

The Company believes the customer base for the ORhub Software is readily identifiable. There are approximately 5,600 hospitals in the United States. But, the top 12 hospital ownership groups control roughly 20% of the market. Initially, because of the

---

#### **ORHUB, INC.**

OTC PINK BASIC QUARTERLY INFORMATION  
AND DISCLOSURE STATEMENT  
AS OF THE QUARTER ENDING MARCH 31, 2017

Company's extensive access to these top-tier markets through our Surgical Business and Technical Advisory Board and the Company's development partners, we intend to focus our marketing efforts on these groups and initially on those hospitals considered leaders in spine surgery related to the aging spine, degenerative disc disease, and complex reconstructive deformity procedures. The Company believes that by penetrating this target group, other less complex market segments will more readily follow.

- B. Date and State (or Jurisdiction) of Incorporation: September 8, 2005/Nevada
- C. the Company's primary and secondary SIC Codes: 7372
- D. the Company's fiscal year end date: June 30
- E. principal products or services, and their markets: The Company is continuing to develop software that it intends to monetize by selling per use subscriptions for the software

**ITEM 7) DESCRIBE THE ISSUER'S FACILITIES**

We sub-lease approximately 500 square feet of administrative office space in Phoenix, Arizona through February 2017. We lease a development office in Bellevue, Washington in an executive suite. We have entered an 18-month lease for 873 square feet which commenced January 1, 2017. The Company believes additional and alternative office space is readily available.

**ITEM 8) OFFICERS, DIRECTORS, AND CONTROL PERSONS**

A. Names of Officers, Directors, and Control Persons.

1. Management

Colton Melby, Chief Executive Officer  
Cyrus Olsen, Chief Operating Officer  
Michael S. Williams, Executive Vice-president  
Lanny R. Lang, Chief Financial Officer  
Wesley Mitchell, Chief Technical Officer

2. Board of Directors

Colton Melby, Chairman of the Board  
Michael S. Williams, Director  
Corey Lambrecht, Director

3. Surgical Business and Technical Advisory Board and Control Persons

Williams Dobkin, MD  
 Christopher Wiggins  
 Richard Lee, MD

B. Legal/Disciplinary History. None of our Officers, Directors or Control Persons have, in the last five years, been the subject of: (1) A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses); (2) The entry of an order, judgment, or decree, not subsequently reversed, suspended, or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities; (3) A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or (4) The entry of an order by a self-regulatory organization that permanently or temporarily barred suspended or otherwise limited such person's involvement in any type of business or securities activities.

C. Beneficial Stockholders. The following table sets forth the name, address, and shareholdings or the percentage of shares owned by all persons beneficially owning more than ten percent (10%) of any class of the Company's equity securities.

**Beneficial Ownership Table**

Name of Beneficial Owner	Number of Shares Beneficially Owned	Percentage Beneficially Owned (1)
Colton Melby (2) 12025 DE OR Drive, Dallas, TX 75230	16,828,018	13.3%
Christopher Wiggins (3) (5) 15785 Laguna Canyon Road, Suite 125, Irvine, CA 92618	21,983,936	17.2%
William Dobkin, MD (4) (5) Hoag Neuroscience Institute c/o Dr. William Dobkin, 3900 W. Coast Hwy, Suite 300, Newport Beach, CA 92663	24,966,514	19.5%
Richard Lee, MD (5) Hoag Orthopedic Institute c/o Dr. Richard Lee 16250 Sand Canyon Ave., Irvine, CA 92618	15,262,884	11.9%
Wesley Mitchell (6)	16,578,018	13.0%

10900 NE 4th Street, Suite 2430, Bellevue, WA 98004

**Footnotes to the Beneficial Ownership Table**

- (1) Based on 127,791,444 shares of our common stock outstanding.
- (2) This includes 16,578,018 shares held by Castillo de Coachella, LLC, beneficially owned by Mr. Melby and includes all 125,000 vested stock options held by Castillo Misterio, LLC with a \$.33 exercise price beneficially owned by Mr. Melby.
- (3) This includes 21,833,936 shares held by Wylde, LLC, beneficially owned by Mr. Wiggins and this includes all Mr. Wiggins' 100,000 vested stock options for his Advisory Board Service with a \$.33 exercise price.
- (4) This includes 24,866,514 shares held by JAATRL, LLC, beneficially owned by Dr. Dobkin and this includes all Dr. Dobkin's 100,000 vested stock options for his Advisory Board Service with a \$.33 exercise price.
- (5) This includes 15,212,884 shares held by OR Lstock, L.L.C. and beneficially owned by Dr. Lee and also includes all Dr. Lee's 100,000 vested stock options for his Advisory Board Service with a \$.33 exercise price.
- (6) All these shares are held by Sudden Valley, LLC., beneficially owned by Mr. Mitchell.

**ITEM 9) THIRD PARTY PROVIDERS** (these are Company's only 3<sup>rd</sup> party providers)

1. Legal Counsel:

Name: Thomas J. Morgan  
Firm: Sherman & Howard L.L.C  
Address 1: 201 East Washington Street, Suite 800  
Address 2: Phoenix, Arizona 85004  
Phone: (602) 240-3000  
Email: [tmorgan@shermanhoward.com](mailto:tmorgan@shermanhoward.com)

2. Accountant:

Name: Malone & Bailey LLP.  
Contact: Jimmy Thompson  
Address 1: 9801 Westheimer Rd., Suite 1100  
Address 2: Houston, Texas 77042  
Phone: (713) 343-4246  
Email: [jthompson@malonebailey.com](mailto:jthompson@malonebailey.com)

3. Investor Relations and General Consultant:

Communications Contact:  
NetworkNewsWire (NNW) [www.NetworkNewsWire.com](http://www.NetworkNewsWire.com)  
1324 Lexington Ave., Suite 117  
New York, New York 10128  
(212) 418.1217  
[editor@NetworkNewsWire.com](mailto:editor@NetworkNewsWire.com)

---

**ORHUB, INC.**

OTC PINK BASIC QUARTERLY INFORMATION  
AND DISCLOSURE STATEMENT  
AS OF THE QUARTER ENDING MARCH 31, 2017

**ITEM 10) ISSUER CERTIFICATION**

Certifications by the chief executive officer and chief financial officer of the Issuer.

A. Chief Executive Officer Certification

I, Colton Melby, certify that:

1. I have reviewed this ORhub, Inc.'s Quarterly Disclosure Statement for the Company's third fiscal Quarter ending March 31, 2017;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

/s/ Colton Melby  
Colton Melby,  
Chief Executive Officer

May 19, 2017  
Date

**ITEM 10) ISSUER CERTIFICATION (CONTINUED)**

**B. Chief Financial Officer Certification**

I, Lanny R. Lang, certify that:

4. I have reviewed this ORhub, Inc.'s Quarterly Disclosure Statement for the Company's third fiscal Quarter ending March 31, 2017;

1.

2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and

3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

/s/ Lanny R. Lang  
Lanny R. Lang,  
Chief Financial Officer

May 19, 2017  
Date